Skip to main content
Fig. 4 | Microbial Cell Factories

Fig. 4

From: Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents

Fig. 4

Comparison of microorganisms’ sensitivity to the antibacterial peptides produced by P. aeruginosa clinical isolates (A) and comparison of antibacterial potential CFS of Isolates (B). Figure 4A shows the average inhibition zone of each indicator strain in the vicinity of all peptides of P. aeruginosa clinical isolate (A18, B79, B92, B94, B95, C104, C107, C108, C115, D121, D126, D130, D133). Figure B shows the average total antibacterial effects of the peptides of each P. aeruginosa clinical isolates against all 7 indicator strains (S. epidermidis, P. mirabilis, P. vulgaris, S. aureus, S. mutans, S. pyogenes and E. hirae). In other words, the average inhibition zone of all 7 indicator strains in the vicinity of the antibacterial peptide of each isolate is reported. W.m without Mitomycin C, M Mitomycin C

Back to article page

Microbial Cell Factories

ISSN: 1475-2859

Contact us